The 2019 Genitourinary Cancers Symposium will feature new research on treatments for prostate cancer and kidney cancer.

In this podcast, Cancer.Net Associate Editor Dr. Michael Williams describes lymphoma research advances presented at the American Society of Hematology Annual Meeting.

In this podcast, Dr. Brian Rini and Dr. Jorge Garcia discuss the latest research in genitourinary cancers presented at the 2018 ESMO Congress.

Some recent FDA approvals have made many people aware of tumor-agnostic treatments. But what does that mean and how could it benefit someone with cancer? ASCO Chief Medical Officer Richard L. Schilsky gives insight into this new way of thinking about cancer treatment.

Research highlights from the 2018 Palliative and Supportive Care in Oncology Symposium include an AI-based app that helps reduce the burden of cancer-related pain and an awareness that immunotherapy may cause more side effects than originally thought.

Kidney cancer is the sixth most common cancer for men and the tenth most common cancer for women. Cancer.Net Associate Editor Brian Rini, MD, shares 4 things people need to know about kidney cancer.

Cancer.Net Associate Editors discuss exciting and practice-changing cancer research from ASCO Annual Meeting in this Research Round Up podcast.

Lung cancer affects tens of thousands of Americans every year. In this blog post, Cancer.Net Associate Editor Dr. Jyoti Patel describes 9 things every person should know about lung cancer.

Oncology professionals from around the globe are at the 2018 ASCO Annual Meeting. Today’s key research highlights include new treatment options and improved survival for breast cancer, kidney cancer, non-small cell lung cancer, and rhabdomyosarcoma.

Oncology professionals from around the globe are at the 2018 ASCO Annual Meeting. Today’s key research highlights address the connection between microsatellite instability and Lynch syndrome, a blood test that may be used to find early lung cancer, a new targeted therapy for treating advanced breast cancer, an immunotherapy-chemotherapy combination that slows lung cancer growth, and evidence that personalized medicine helps people with cancer live longer.